drugset / Trial / NCT00470405

Pemetrexed and Oxaliplatin in Treating Patients With Metastatic Solid Tumors or Lymphoma

NCT00470405

NaSingle-groupOpen-labelTreatment

Summary

RATIONALE: Pemetrexed may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as oxaliplatin, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving pemetrexed together with oxaliplatin may kill more cancer cells. PURPOSE: This phase I trial is studying the side effects and best dose of pemetrexed given together with oxaliplatin in treating patients with metastatic solid tumors or lymphoma.

Timeline

Start
2004-05
Primary completion
2007-05
Completion
2007-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Oxaliplatin Small molecule 85 mg/m2 Intravenous
Subject Pemetrexed Small molecule 300 mg/m2 Intravenous
Subject Pemetrexed Small molecule 400 mg/m2 Intravenous
Subject Pemetrexed Small molecule 500 mg/m2 Intravenous

Indications